Registry for Bone Metastases

The International Bone Metastasis Registry

The purpose of this study is to learn more about symptomatic bone metastases. This study is an international patient registry of people with symptomatic bone metastases. A patient registry is a database - a collection of health information - about a group of people, and it is usually focused on a specific diagnosis or condition.

Study Overview

• Status: Recruiting
• Conditions: Bone Metastases

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076; Email: forsbej@mskcc.org
• Study Contact Backup: Name: Carol Morris, MD; Phone Number: 212-639-7611

Study Locations

• United States
  • New Jersey
    • Basking Ridge, New Jersey, United States, 07920
      • Recruiting
      • Memorial Sloan Kettering Basking Ridge (All protocol activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076
    • Middletown, New Jersey, United States, 07748
      • Recruiting
      • Memorial Sloan Kettering Monmouth (All protocol activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076
    • Montvale, New Jersey, United States, 07645
      • Recruiting
      • Memorial Sloan Kettering Bergen (All protocol activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076
  • New York
    • Commack, New York, United States, 11725
      • Recruiting
      • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076
    • Harrison, New York, United States, 10604
      • Recruiting
      • Memorial Sloan Kettering Westchester (All protocol activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076
    • New York, New York, United States, 10065
      • Recruiting
      • Memorial Sloan Kettering Cancer Center (All protocol activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076
      • Principal Investigator: Jonathan Forsberg, MD, PhD
    • Uniondale, New York, United States, 11553
      • Recruiting
      • Memorial Sloan Kettering Nassau (All protocol activities)
      • Contact: Jonathan Forsberg, MD, PhD; Phone Number: 212-639-2076

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

There is also a retrospective component to this study, in which we will review data on patients going back to 2015; we will analyze data from any patients who died with symptomatic metastatic bone disease for possible inclusion in the IBMR. Living patients will be prospectively enrolled into the trial.

For the retrospective component, only deceased patients (500) will be analyzed.

Description

Inclusion Criteria:

• Age ≥22 years
• Biopsy-proven or clinically obvious metastatic bone disease
• Symptomatic bone lesion requiring intervention
• This includes but is not limited to radiotherapy, cryotherapy, radiofrequency ablation, operative fixation, prosthetic replacement, amputation, or any combination of the above

Exclusion Criteria:

• Age <22 years

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Bone Metastases

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
overall survival	10 years

Collaborators and Investigators

• Sponsor: Memorial Sloan Kettering Cancer Center
• Investigators: Principal Investigator: Jonathan Forsberg, MD, PhD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

Helpful Links

• Memorial Sloan Kettering Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): January 13, 2026
• Primary Completion (Estimated): January 1, 2031
• Study Completion (Estimated): January 1, 2031

Study Registration Dates

• First Submitted: January 23, 2026
• First Submitted That Met QC Criteria: January 29, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): April 22, 2026
• Last Update Submitted That Met QC Criteria: April 21, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: 23-175
• Other Study ID Numbers: 23-175

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No